Meeting Coverage

Neurite orientation dispersion and density imaging (NODDI) can detect brain microstructural and metabolic alterations after the first demyelinating event in MS [1]. There was increased axonal dispersion in normal-appearing white...

People with MS are not more susceptible to COVID-19 infection than the UK general population, suggest results of the largest community-based study of COVID-19 in people with MS worldwide [1]. During lockdown, with strict...

No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...

Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...

Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...

Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...

Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...

Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...

For one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...

In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....